Skip to content

Brazil Anti-Rheumatic Drug Market Forecasts Report 2022: A

Dublin, Jan. 17, 2023 (GLOBE NEWSWIRE) — The “Brazil Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s providing.

The Brazilian anti-rheumatic medication market was valued at US$2,400.050 million in 2020. The market is projected to develop at a CAGR of two.41% to achieve a worth of US$2,836.140 million by 2027.

The rising growing old inhabitants in Brazil is the most important issue that’s driving the demand for antirheumatic medication within the nation. The restoration of the Brazilian economic system could be witnessed by rising buying energy and a corresponding shift in the direction of a fast-food weight-reduction plan, resulting in rising circumstances of weight problems and diabetes within the nation.

In line with the World Well being Group (WHO), the prevalence of diabetes has elevated steadily since 1980, with 7.4% of males and eight.8% of females affected by diabetes in Brazil. Moreover, half of the Brazilian inhabitants is obese, whereas 20% are overweight. As such, the variety of circumstances of arthritis is rising within the nation, thereby driving the market development of antirheumatic medication.

The rise within the gross sales of generic medication in Brazil owing to the Generic Medicines Coverage handed in 1999 by the Brazilian authorities is one other issue that’s boosting the expansion of the nation’s antirheumatic drug market. Since many Brazilians nonetheless can’t afford drugs, the event of low-cost generic medication helps to develop entry to extra underserved populations.

Moreover, the Brazilian Institute of Geography and Statistics estimated that the senior inhabitants of Brazil will surpass its younger inhabitants over the following twenty years, which additional drives the necessity for quite a lot of reasonably priced medicines for age-related ailments in an effort to keep the general healthcare expense.

The Brazilian Antirheumatic Medicine market has been segmented based mostly on the kind of illness, kind of molecule, and gross sales channel. By kind of illness, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By kind of molecule, the Brazilian antirheumatic medication market has been labeled into prescribed drugs and biopharmaceuticals. The market segmentation has additionally been finished by gross sales channel as prescription and over-the-counter (OTC).

Key Developments within the Market:

In April 2022, South Korean-based Cellitron introduced that it has gained a young from the Brazilian Federal Authorities for buying Infliximab biosimilar, Remsima. Infliximab is used to deal with a number of situations associated to rheumatic situations, together with psoriatic arthritis and rheumatic situations, amongst many others.

In line with the agency, this profitable bid was a big milestone, widening the affected person’s entry to reasonably priced and efficient biosimilar medication in international locations like Mexico and Brazil, the 2 largest pharmaceutical markets in South America.

COVID-19Insights:

COVID-19 had a big influence on the Brazilian antirheumatic medication market. The rising prevalence of arthritis-related situations amongst all ages of the inhabitants has elevated the demand for the medication.

Nevertheless, mandated lockdown and social distancing measures enforced in Brazil led to the closure of a number of manufacturing amenities and witnessed low staffing, decreasing productiveness. The journey restrictions additionally affected the exports and imports of the market, creating a spot within the provide and demand chain. Comparable elements had slowed down the market’s development.

Key Metrics

Report Attribute Particulars
No. of Pages 76
Forecast interval 2020 – 2027
Estimated Market Worth (USD) in 2020 $2400.05 million
Forecasted Market Worth (USD) by 2027 $2836.14 million
Compound Annual Progress Fee 2.4%
Areas Lined Brazil

Corporations Talked about

  • AbbVie Inc.
  • Amget Inc.
  • Johnson and Johnson
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Eli Lilly and Firm
  • Novartis AG
  • Celgene Company (Bristol-Myers Squibb)
  • Eisai Co.,Ltd.

segmentation

By Kind of Illness

  • osteoarthritis
  • Rheumatoid Arthritis
  • gout
  • Lupus

By Drug Class

  • Illness-modifying Anti-Rheumatic Medicine (DMARDs)
  • Nonsteroidal Anti-inflammatory Medicine (NSAIDs)
  • Corticosteroids
  • JAK inhibitor

By Gross sales Channel

  • prescription
  • Over-The-Counter (OTC)

For extra details about this report go to https://www.researchandmarkets.com/r/synwac

AboutResearchAndMarkets.com
ResearchAndMarkets.com is the world’s main supply for worldwide market analysis stories and market knowledge. We give you the most recent knowledge on worldwide and regional markets, key industries, the highest firms, new merchandise and the most recent tendencies.

  • Brazilian Anti-Rheumatic Drug Market

        

.

Leave a Reply

Your email address will not be published. Required fields are marked *